Current management of acromegaly

Expert Opinion on Pharmacotherapy

Volumn 1, Issue 5, 2000, Pages 991-1006

  Díez, Juan J ^a   Iglesias, Pedro ^b  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b HOSPITAL GENERAL DE SEGOVIA   (Spain)

Author keywords

Acromegaly; Acromegaly treatment; Dopamine agonists; Radiotherapy; Somatostatin analogues; Transsphenoidal surgery

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; HORMONE ANTAGONIST; SOMATOSTATIN;

ACROMEGALY; ADENOMA; HUMAN; HYPOPHYSIS TUMOR; METABOLISM; REVIEW;

ACROMEGALY; ADENOMA; DOPAMINE AGONISTS; HORMONE ANTAGONISTS; HUMANS; PITUITARY NEOPLASMS; SOMATOSTATIN;

EID: 0034232054     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.1.5.991     Document Type: Article

References (86)

1. MELMED S: Acromcgaly. ff. Engl. J. Med. (1990) 322:966-977. One of the most cited papers on the clinical aspects of acromegaly.
2. NABARRO JDN: Acromcgaly. Clin. Endocrinol. (Oxf) (1980) 26:481-512. A classic reading for those interested in acromegaly.
3. BATES AS, VANT HOFF W, JONES JM, CLAYTON RN: An audit of outcome of treatment in acromegaly. Q.J. Med. (1993) 86:293-299. An important article that relates growth hormone levels with mortality in acromegalic patients.
4. FAHLBUSCH F, HONEGGER J, BUCHFELDER M: Surgical management of acromegaly. Endocrinol. Metab. Clin. North Am. (1992) 21:669-692. An interesting review of surgery in acromegaly. Surgical results in 224 patients are discussed.
5. DIEZ JJ: Conceptos actuates en el diagnóstico y tratamiento de la acromegalia. Rev. Clin. Esp. (1996) 196:622-635.
6. GARCIA-URIA J, LUCAS T, CUERDA C et al.: Acromegaly: long-term surgical results in 300 patients./ Endocrinol. Invest. (1997) 20(Suppl. 7):98.
7. FREDA PU, WARDLAW SL, POST KD: Long-term endocrinologie follow-up after transsphenoidal surgery for acromegaly./ Keumsiirg. (1998) 89:353-358.
8. AHMED S, ELSHEIKH M, STRATTON IM, PAGE RCL, ADAMS CBT, WASS JAH: Outcome of transsphenoidal surgery for acromegaly and its relationship to surgical experience. Clin. Endocrinol. (Oxf) (1999) 50:561-567. A series of 139 patients operated on by one surgeon.
9. GITTOES NJL, SHEPPARD MC, JOHNSON AP, STEWART PM: Outcome of surgery for acromegaly-the experience of a dedicated pituitary surgeon. Q.J. Med. (1999) 92:741-745.
10. ABOSCH A, TYRRELL JB, LAMBORN R, HANNEGAN LT, APPLEBURY CB, WILSON CB: Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. / Clin. Endocrinol. Metab. (1998) 83:3411-3418. A surgical series of 254 patients.
11. SWEARINGEN B, BARKER FG, KATZNELSON L et al.: Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J. Clin. Endocrinol. Metab. (1998) 83:3419-3426. A surgical series of 162 patients..
12. JHO HD: Endoscopie cndonasal transsphenoidal surgery. Proceedings of the 6th International Pituitary Congress. Long Beach, California, USA (1999):29.
13. EASTMAN RC, GORDEN P, GLATSTEIN E, ROTH J: Radiation therapy of acromegaly. Endocrinol. Metab. Clin. North Am. (1992) 21:693-712. Excellent review of conventional radiotherapy for acromegaly.
14. EASTMAN RC, GORDEN P, ROTH J: Conventional supcrvoltage irradiation is an effective treatment for acromegaly./ Clin. Endocrinol. Metab. (1979) 48:931-940.
15. CLARKE SD, WOO SY, BUTLER EB et al.: Treatment of secretory pituitary adenoma with radiation therapy. Radiology (.\y)S> 188:759-763.
16. JACKSON IMD, NOREN G: Role of gamma knife therapy in the management of pituitary tumors. Endocrinol. Metab. Clin. North Am. (1999) 28:133-142. An updated review of y knife radiosurgery.
17. LANDOLT AM, HALLER D, LOMAX N et al: Stcrcotactic radiosurgery for recurrent surgically treated acrotnegaly: comparison with fractionated radiotherapy./ Kenrosiirg. (1998) 88:1002-1008.
18. THOREN M, RAHN T, GUO WY, WERNER S: Stereotactic radiosurgery with the cobalt-60 gamma-unit in the treatment of growth hormone-producing pituitary tumors. Keitrosurgery (1991) 29:663-668.
19. MELMED S, JACKSON I, KLEINBERG D, KLIBANSKI A: Current treatment guidelines for acromegaly. / Clin. Endocrinol. Metab. (1998) 83:2646-2652. A summary of diagnostic procedures followed by treatment guidelines for acromegaly.
20. FREDA PU, WARDLAW SL: Diagnosis and treatment of pituitary tumors. J. Clin. Endocrinol. Metab. (1999) 84:3859-3866. An updated review of the diverse modalities of therapy for pituitary tumours.
21. BARKAN AL, HALASZ I, DORNFELD KJ et al.: Pituitary irradiation is ineffective in normalizing plasma insulin-like growth Factor I in patients with acromegaly. J. Clin. Endocrinol. Metab. (1997) 82:3187-3191. A notable article on the long-term evaluation of the hormonal effects of radiation.
22. JAFFE CA, BARKAN AL: Treatment of acromegaly with dopaminc agonists. Endocrinol. Metab. Clin. Kortb Am. (1992) 21:713-735. Excellent review on dopamine agonists, with special reference to bromocriptine.
23. CICCARELLI F, MIOLA C, GROTTOLI S, AVATANEO T, LANCRANJAN I, CAMANNI F: Long-term therapy of patients with macroprolactinoma using repcatablc injectable bromocriptine. J. Clin. Endocrinol. Metab. (1993) 76:484-488.
24. CHIODINI PG, ATTANASIO R, COZZI R étal.: CV 205-502 in acromegaly. Acta Endocrinol. (Copenh) (1993) 128:389-393.
25. LOMBARDI G, COLAO A, FERONE D et al.: CV 205-502 treatment in therapy-resistant acromegalic patients. Eur.J. Endocrinol. (1995) 132:559-564.
26. COZZI R, ATTANASIO R, BARAUSSE M et al.: Cabergoline in acromcgary: a renewed role for dopaminc agonist treatment? Eur.J. Endocrinol. (1998) 139:516-521.
27. COLAO A, FERONE D, MARZULLO P et al.: Effect of different dopamincrgic agents in the treatment of acromegaly./ Clin. Endocrinol. Metab. (1997) 82:518-523. A very interesting paper dealing with dopamine agonists in acromegaly.
28. JASPERS C, HAASE R, PFINGSTEN H et al.: Long-term treatment of acromegalic patients with repcatablc parcntcral depot-bromocriptine. Clin Invest. (1993) 71:547-551.
29. ABS R, VERHELST J, WAITER D et al.: Cabergoline in the treatment of acromcgary: a study in 64 patients./ Clin. Endocrinol. Metab. (1998) 83:374-378. An interesting article on the effects of the new dopamine agonist cabergoline.
30. MELMED S, HO K, KLIDANSKI A, REICHLIN S, THORNER M: Recent advances in pathogcncsis, diagnosis and management of acromegaly. J. Clin. Endocrinol Metab. (1995) 80:3395-3402. A review published in 1995 with valuable information.
31. LANCRANJAN I, BURNS C, GRASS P et al.: Sandostaün LAR®: pharmacokinetics, phartnacodynamics, efficacy and tolerability in acromcgalic patients. Metabolism (1995) 44(Suppl. l):18-26. A thorough study of the pharmacokinetics and pharmacodynamics of the slow release formulation of octreotide.
32. DAVIES PH, STEWART SE, LANCRANJAN I, SHEPPARD MC, STEWART PM: Long-term therapy with long-acting octreotide (Sandostatin LAR) for the management of acromegaly. Clin. Endocrinol. (0x0(1998) 48:311-316.
33. LANCRANJAN I, ATKINSON AD AND THE SANDOSTATIN® LAR® GROUP: Results of a European Multicentre Study with Sandostatin® LAR® in acromcgalic patients. Pituitary (1999) 1:105-114. A very interesting paper, focusing on the results of a multicentre study, where 151 patients were treated with octreotide LAR.
34. FLØGSTAD AK, HALSE J, BAKKE S et al.: Sandostatin LAR in acromegalic patients: long term treatment J. Clin. Endocrinol. Metab. (1997) 82:23-28.
35. HERON I, THOMAS F, DERO M et al.: Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly./ Clin. Endocrinol. Metab.(l995) 76:721-721. One of the first papers analysing the pharmacokinetics and pharmacodynamics of the slow release formulation of lanreotide.
36. REISINE T, BELL GI: Molçfular biology of somatostatin receptors. Enclocr. Rev. (1995) 16:427-442. Excellent review on somatostatin receptors.
37. EZZAT S, SNYDER PJ, YOUNG WF et al.: Octreotide treatment of acromegaly: a randomized, multicenter study. Ann. Intern. Meet. (1992) 117:711-718. An excellent randomised study on the effects of sc. octreotide.
38. NEWMAN CB, MELMED S, SNYDER PJ et al.: Safety and efficacy of long term octreotide therapy of acromegaly: results of a multicenter trial in 103 paticnts-a clinical research center study. / Clin. Endocrinol. Metab. (1995) 80:2768-2775-A multicentre study with a great number of patients treated with sc. octreotide for 3-30 months.
39. NEWMAN CB, MELMED S, GEORGE A et al.: Octreotide as primary therapy for acromegaly. / Clin. Endocrinol. Metab. (1998) 83:3034-3040. Excellent study comparing octreotide sc. as primary therapy for acromegaly, with octreotide sc. as adjunctive or secondary therapy after surgery or pituitary radiation.
40. LAMBERTS SWJ, VAN DER LELY AJ, DE HERDER WW, HOFLAND LJ: Octreotide. Ar. Engl. J. Med. (1996) 334:246-254. Splendid review of the clinical applications of octreotide.
41. COLAO A, CUOCOLO A, MARZULLO P et al.-. Effects of a 1-year treatment with octreotide on cardiac performance in patients with acromcgaly. J. Clin. Etulocrinol. Metab. (1999) 84:17-23. A study on the cardiac effects of octreotide.
42. LANCRANJAN I, BRUNS C, GRASS P et ah. Sandostatin LAR®: a promising therapeutic tool in the management of acromegalic patients. Metabolism (1996) 45(8) (Suppl. 1):67-71.
43. MORANGEI, DE BOISVILLIERS F, CHANSON P et al.-. Slow release lanreotidc treatment in acromegalic patients previously normalized by octreotide. J. Clin. Endocrinol. Metab. (1994) 79:145-151. A study comparing the efficacy of octreotide sc. and SR lanreotide.
44. MAREK J, HANA V, KRSEK M, JUSTOVA V, CATUS F, THOMAS F: Long-term treatment of acromcgaly with the slow-release somatostatin analogue lanreotidc. Eur.J. Endocrinol. (1994) 131:20-26. Interesting paper on the long-term results of lanreotide therapy.
45. JOHNSON MR, CHOWDREY HS, THOMAS F, GRINT C, LIGHTMAN SL: Pharmacokinctics and efficacy of the long-acting somatostatin analogue somatuline in acromegaly. Eur.J. Endocrinol. (1994) 130:229-234.
46. AL-MASKAR1 M, GEBBIE J, KENDALL-TAYLOR P: The effect of a new slow-release, long-acting somatostatin analogue, lanreotide, in acromcgaly. Clin. Endocrinol. (Oxf) (1996) 45:415-421.
47. GIUSTI M, GUSSONIG, CUTTICA CM, GIORDANO G, AND THE ITALIAN MULTICENTER SLOW RELEASE LANREOTIDE STUDY GROUP: Effectiveness and tolerabUity of slow release lanreotide treatment in active acromegaly: six month report on an Italian Multicenter study. / Clin. Endocrinol. Metab. (1996) 81:2089-2097.
48. A multicentre study in 56 unselected patients with active acromegaly.
49. GIUSTI M, CICCARELLI E, DALLABONZANA D et al.: Clinical results of long-term slow-release lanreotide treatment of acromegaly. Ettr. J. Clin. Invest. (1997) 27:277-284.
50. CARON P, MORANGE-RAMOS I, COGNE M, JAQUET P: Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotidc. / Clin. Endocrinol. Metab. (1997) 82:18-22.
51. A study confirming the efficacy of the long-term SR lanreotide therapy.
52. SULIMAN M, JENKINS R, ROSS R, POWELL T, BATTERSBY R, CULLEN DR: Long-term treatment of acromcgaly with the somatostatin analogue SR-lanrcotidc. J.
53. Endocrinol. Invest. (1999) 22:409-418.
54. COLAO A, MARZULLO P, FERONE D et al.-. Effectiveness and tolerabUity of slow release lanreotidc treatment in active acromegaly./ Endocrinol. Invest. (1999) 22:40-47.
55. BALDELLIR, FERRETTI E, JAFFRAIN-REA ML et al: Cardiac effects of slow-release lanreotide, a slow-release somatostatin analogue, in acromegalic patients./ Clin. Endocrinol. Metab. (1999) 84:527-532.
56. HUNTER SJ, SHAW JAM, LEE KO, WOOD PJ, ATKINSON AB, BEVAN JS: Comparison of monthly intramuscular injection of Sandostatin LAR with multiple subcutaneous injections of octreotide in the treatment of acromegaly; effects on growth hormone and other markers of growth hormone secretion. Clin. Endocrinol. (Ox/) (1999) 50:245-251. Interesting work comparing the two formulations of octreotide.
57. NEWMAN CB: Medical therapy for acromegaly. Endocrinol. Metab. Clin. North. Am. (1999) 28:171-190. An updated review of the pharmacological therapy for acromegaly.
58. DIEZ JJ: Lanrcotida: una nucva opcion terapcutica en la acromcgalia. Med. Clin. (Bare) (1996) 107:247-269.
59. TURNER HE, VADIVALE A, KEENAN J, WASS JAM: A comparison of lanrcotide and octreotide LAR for treatment of acromegaly. Clin. Endocrinol. CO./) (1999) 51:275-280. A paper comparing lanreotide and octreotide in their sustained release formulations, in a group of 10 patients with acromegaly.
60. COZZI R, DALLABONZANA D, ATTANASIO R, BARAUSSE M, OPPIZZI G: A comparison between octreotide-LAR and lanrcotide-SR in the chronic treatment of acromegaly. Eur.J. Endocrinol. (1999) 141:267-271. Another comparative study of 12 patients.
61. BARKAN AL, LLOYD RC, CHANDLER WF et al.: Preoperattvc treatment of acromegaly with long-acting somatostatin analog SMS 201-995: shrinkage of invasive pituitary macroadcnomas and improved surgical remission rate. / Clin. Endocrinol. Metab. (1988) 67:1040-1048.
62. GILLIS JC, NOBLE S, GOA KL: Octreotide long-acting release (LAR): a review of its pharmacological properties and therapeutic use in the management of acromegaly. Drugs (1997) 53:681-699. A good review of the pharmacology of octreotide LAR.
63. RAZZORE P, COLAO A, BALDELLI R et al.: Comparison of six months therapy with octreotide versus lanreotide in acromegalic patients: a retrospective study. Clin. Endocrinol. (ÖX/X1999) 51:159-164.
64. THORNER MO, STRASBURGER CJ, WU Z et al.: Growth hormone (GH) receptor blockade with a PEG-modified GH (B2036-PEG) lowers scrum insulin-like growth factor-I but does not acutely stimulate serum GH. J. Clin. Endocrinol. Metab. (1999) 84:2098-2103. A clinical study on the new drug pegvisomant.
65. HUTSON RK, LIPPER M: The novel growth hormone receptor antagonist B2036-PEG does not stimulate growth of pituitary tumors in acromegalic patients (abstract). Proceedings ofTlje 6th International Pituitary Congress. Long Beach, CA, USA (12-15 June 1999):74.
66. TRAINER PJ, DRAKE WM, KATZNELSON L et al.: Treatment of acromegaly with the growth hormone receptor antagonist pegvisomant. N. Engl.J. Med. (2000) 342:1171-1177.
67. A double-blind, placebo-controlled, trial with the new drug pegvisomant in acromegalics
68. RAJASOORYA C, HOLDAWAY IM, WRIGHTSON P, SCOTT DJ, IBBERTSON HK: Determinants of clinical outcome and survival in acromegaly. Clin. Endocrinol. (Oxf) (1994) 41:95-102.
69. SHEPPARD MC: Aims of treatment and definition of
70. cure. In: Treating Acromegaly - 100 Years On. Wass JAM (Ed.), Society for Endocrinology, Bristol, UK (1994):17-23.
71. DUNCAN E, WASS JAH: Investigation protocol: acromegaly and its investigation. Clin. Endocrinol. (Oxf) (1999) 50:285-293. Good review on pathophysiology and diagnosis of acromegaly.
72. ACROMEGALY THERAPY CONSENSUS DEVELOPMENT PANEL: Consensus statement: benefits versus risks of medical therapy for acromegaly. Am. J. Ated. (1994) 97:468-473.
73. A consensus (discussed in 1993 and published in 1994) on the different forms of therapy for acromegaly.
74. GIUSTINA A, BARKAN A, CASANUEVA F et al.: Criteria for cure of acromegaly: a consensus statement. J. Clin. Endocrinol. Metab. (2000) 85:526-529.
75. The most recent consensus statement on criteria for cure of acromegaly.
76. STEVENAERT A, DECKERS A: Presurgical octreotide treatment in acromegaly. Acta Endocrinol. (1993) 129(Suppl. 1):18-20.
77. LUCAS-MORANTE T, GARCIA-URIA J, ESTRADA J et at.: Treatment of invasive growth hormone pituitary adenomas with long-acting somatostatin analog SMS 201-995 before transsphcnoidal surgery. J. Kettrostirg. (1994) 81:10-14.
78. GIOVANELLI M, LOSA M, MORTINI P: Acromegaly: surgical results and prognosis. In: Pituitary Adenomas.
79. Landolt AM, Vance ML, Reilly PL (Eds.), Churchill Livingstone, NY, USA (1996):333-351.
80. KRISTOF RA, STOFFEL-WAGNER B, KLINGMÜLLER D, SCHRAMM J: Does octreotide treatment improve the surgical results of macro-adenomas in acromegaly? A randomized study. Acta Neurochir. (Wien) (1999) 141:39905
81. A prospective, controlled randomised study on preoperative treatment of acromegaly with octreotide sc.
82. BIERMASZ NR, VAN DULKEN H, ROELFSEMA F: Direct postoperative and follow-up results of transsphenoidal surgery in 19 acromegalic patients pretreated with octreotide compared to those in untreated matched controls. / Clin. Endocrinol. Metab. (1999) 84:3551-3555.
83. COLAO A, FERONE D, CAPPABIANCA P et al: Effect of octreotide prctrcatmcnt on surgical outcome in acromegaly. J. Clin. Endocrinol. Metab. (1997) 82:3308-3314.
84. A study on the effect of preoperative treatment with octreotide, focusing on cardiovascular effects, glucose and lipid profile.
85. GARCIA-URIA J, LUCAS T, ALFARO J et al.: The value of preoperative lanrcotidc in acromegaly (abstract).
86. Proceedings of The 6th International Pituitary Congress. Long Beach, CA, USA. (12-15 June 1999):73.